Y-mabs Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Y-mAbs Therapeutics, Inc. has completed its acquisition by Perseus BidCo US, Inc. and Yosemite Merger Sub, Inc. for approximately $413 million, leading to its delisting from Nasdaq.
Y-mAbs Therapeutics reports Q2 2025 financial results, exceeding revenue guidance, alongside a definitive agreement for SERB Pharmaceuticals to acquire the company for $412.0 million.
SERB Pharmaceuticals will acquire Y-mAbs Therapeutics, including its lead oncology asset DANYELZA, for $8.60 per share in an all-cash transaction valued at approximately $412 million.
Y-mAbs Therapeutics, Inc. announced the successful approval of all three proposals, including the election of a Class I director, ratification of its independent auditor, and advisory approval of executive compensation, at its annual meeting of stockholders held on July 11, 2025.
Y-mAbs Therapeutics, Inc. announced complete Part A data from its GD2-SADA Phase 1 Clinical Trial (Trial 1001), validating the safety and tolerability of its pretargeted radioimmunotherapy platform and outlining an expanded oncology pipeline.
Y-mAbs Therapeutics reports an 8% increase in DANYELZA net product revenue for Q1 2025, alongside advancements in their radiopharmaceutical programs.
8-K: Y-mAbs Therapeutics Enters $35 Million Equity Distribution Agreement with Oppenheimer & Co. Inc.
Y-mAbs Therapeutics has entered into an equity distribution agreement with Oppenheimer & Co. Inc. to sell up to $35 million of its common stock through an 'at the market' offering.
Y-mAbs reports increased revenue for Q4 2024 and announces a strategic realignment to focus on radiopharmaceuticals and DANYELZA commercial growth.
Y-mAbs Therapeutics released a corporate overview presentation on January 13, 2025, detailing business, clinical trials, and pipeline updates for investor meetings and the J.P. Morgan Healthcare Conference.
Y-mAbs Therapeutics is realigning its business into two units, reporting preliminary 2024 revenue within guidance, and providing updates on its clinical programs.
Y-mAbs Therapeutics announced its third quarter 2024 financial results, including a 10% revenue decrease, but highlighted a new licensing agreement in Japan and a patent extension for DANYELZA.
Y-mAbs Therapeutics has granted Nobelpharma an exclusive license to develop and commercialize DANYELZA in Japan, potentially expanding its global reach.
Y-mAbs Therapeutics has settled a stockholder derivative lawsuit by canceling stock options and agreeing to enhanced disclosure practices, resolving claims of excessive director compensation.
Y-mAbs Therapeutics has entered into a lease agreement for a new corporate headquarters in Princeton, New Jersey, with an expected move-in during the first half of 2025.
Y-mAbs Therapeutics announced a 10% year-over-year increase in DANYELZA net product revenues for the second quarter of 2024, driven by international expansion.
Y-mAbs Therapeutics has announced the departure of its CFO, Bo Kruse, effective July 31, 2024, and a subsequent consulting agreement with Mr. Kruse's firm.
Y-mAbs Therapeutics has appointed Peter Pfreundschuh as its new Chief Financial Officer, effective June 28, 2024, succeeding Bo Kruse.
Y-mAbs Therapeutics has agreed to a $19.65 million settlement to resolve a securities class action lawsuit, with the majority of the payment expected to be covered by insurance.
Y-mAbs Therapeutics held its annual meeting on June 11, 2024, where shareholders elected three Class III directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation.
Y-mAbs Therapeutics reported a mixed first quarter of 2024, with US DANYELZA sales increasing by 11% year-over-year, while worldwide sales decreased by 4% due to international factors.
Y-mAbs Therapeutics announces the resignation of board member Dr. Grard Ber, effective June 10, 2024, prior to the company's annual meeting.
Y-mAbs Therapeutics' Chief Financial Officer, Bo Kruse, has announced his resignation, effective upon the appointment of his successor, with a planned departure from employment by July 31, 2024.
Y-mAbs Therapeutics has appointed Mary Tagliaferri, M.D., a seasoned biopharmaceutical executive, to its Board of Directors, effective February 29, 2024.
Y-mAbs Therapeutics announced record DANYELZA net product revenues for both the fourth quarter and full year 2023, alongside a positive financial outlook for 2024.